Diabetes

Pharmacists optimize insulin therapy, including basal and bolus dosing, missed-dose tips, continuous glucose monitoring insights, and affordability.

Non-high-density lipoprotein cholesterol matters in type 2 diabetes care and can be managed with statins, combination therapy, and omega‑3s.

Tentative FDA nod for generic semaglutide signals more glucagon-like peptide-1 access, easing pharmacy hurdles and curbing risky compounded alternatives.

Meta-analysis shows CGM lowers HbA1c and hypoglycemia in insulin-treated type 2 diabetes, while pharmacists tackle training, costs, and skin issues.

Researchers assess medication adherence across initial combination therapy users during their first year of type 2 diabetes treatment.

Episode 9 dives into the landscape of obesity pharmacotherapy, detailing current therapies, clinical updates, future pipelines, and more.

Community pharmacists weave brief lifestyle coaching and point-of-care testing into medication management, improving diabetes and hypertension outcomes.

New evidence links poor sleep and diabetes risk to widespread prenatal anxiety, urging pharmacists to support metabolic control and mental health.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

A growing body of evidence suggests that the choice of glucose-lowering therapy may play a critical role in colorectal cancer prevention.

Pharmacists spot diabetes risk early, explain heart- and kidney-protecting meds, decode CGM data, and find affordable support.

Suzanne K. Higginbotham, PharmD, BCACP, CTTS, CDCES, further discusses her APhA 2026 presentation titled “Real-Time. Real Change. Rethinking CGM for Today's Patient.”

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, present on updates to the ADA Standards of Care in Diabetes.

In a bonus episode of the Over the Counter podcast, William A. Bryson, PharmD, joined to help celebrate Diabetes Alert Day—recognized annually on the fourth Tuesday in March.

Lilly’s once-weekly retatrutide lowers A1C up to 2% and drives nearly 17% weight loss in type 2 diabetes, signaling a powerful triple-agonist shift.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

With ongoing concerns about the safety and formulation of compounded GLP-1s, Annie Lambert, PharmD, BCSCP, added her expert insights into the recent crackdown of these products.

Combined with nutritional interventions, semaglutide also demonstrates greater weight loss compared with dulaglutide.

Clinical pharmacists boost A1c control and eye and foot screening for Spanish-speaking adults with diabetes, revealing why culturally fluent care matters.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

In older adults with type 2 diabetes, low body mass index signals higher mortality risk.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.